Respiratory viruses continue to be a fascinating subject. The mutability of these viruses leads to the periodic emergence of new serotypes or species of viruses as human pathogens. Because these viruses are readily transmitted, a new respiratory virus that emerges can spread rapidly. The coronavirus associated with the severe acute respiratory syndrome (SARS) and the novel influenza A (H1N1) virus (swine influenza) are two examples of respiratory viruses that spread very quickly after emerging. According to data from the World Health Organization, there have been 55,867 cases and 238 deaths due to the H1N1 virus to date (http://www.who.int/csr/don/ 2009_06_24/en/index.html, accessed June 25, 2009). This outbreak underscores the importance of our continued attention to the epidemiology, manifestations, and diagnosis of respiratory viruses. Viral culture and immunological assays have been the mainstays of viral diagnosis for decades. These methods are cheaper and technically simpler than the currently available molecular methods, but they are less sensitive than nucleic acid amplified tests (NAATs). Recent improvements in viral culture and immunoassays have led to increased sensitivity, reduced turnaround time, and the ability to detect recently discovered viruses. These improvements are described in the articles by Ms. Riley and myself who discuss viral culture, and Dr. Landry, who discusses immunological assays. Drs. Principi and Esposito extend the discussion of immunoassays with an article on the utility of rapid immunoassays for influenza virus and respiratory syncytial virus (RSV) in children.
There is a revolution underway in the methods for diagnosis of respiratory viruses. NAATs have greatly improved the sensitivity of detection of these viruses. Sophisticated laboratories have been performing user-designed (''home brew'') assays or analyte-specific reagent-based tests, but the recent introduction of NAATs approved by the Food and Drug Administration (FDA) for respiratory viruses will begin to make NAATs accessible to more laboratories. FDA-approved NAATs are discussed by Drs. Kehl and Kumar, who also discuss some important issues to consider in the design of user-developed assays. We take a look at the exciting future of molecular methods of testing for respiratory viruses in the article by Drs. Wu and Tang. 
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